MedTrace Logo

Impact of COX2 on Sera Biomarkers From Obese Subjects

NCT02062255 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2016-10-26

No results posted yet for this study

Summary

Obesity promotes worse outcome for post-menopausal breast cancer patients.

Conditions

  • Breast Cancer Survivors

Interventions

DRUG

Aspirin

DIETARY_SUPPLEMENT

Omega 3 FFA

Sponsors & Collaborators

  • The University of Texas Health Science Center at San Antonio

    lead OTHER

Principal Investigators

  • Andrew Brenner, MD · The University of Texas Health Science Center at San Antonio

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02062255 on ClinicalTrials.gov